Bulk Drug Park in the country :PIB
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
72.5% elderly feel their generation used to spend more time with their elders, 52.4% feel lonely, shows PAN Health’s Liberty in Life of Older People 2022 survey
The Award reinforces Cadila’s digital initiatives which is backed by innovation, research & development and robust frameworks.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
The product will be manufactured at Lupin's facility in Nagpur, India.
Subscribe To Our Newsletter & Stay Updated